title: Prostate cancer in the senior men from rural areas in east district of China: contemporary management and 5-year outcomes at multi-institutional collaboration.
abstract: OBJECTIVE
  Prostate cancer is an underreported and emerging problem in China. Here we summarize the data for Chinese patients with prostate cancer (PCa), describe available treatment options, and report 5-year outcomes at multiple tertiary care institutions.
  
  
  METHODS
  A series of 1611 patients (mean age 76.51 years) diagnosed with PCa were enrolled. Survival rates for patients were analyzed using the Kaplan-Meier method. Prognostic factors for disease-specific survival were analyzed using the log-rank test and Cox proportional hazards model.
  
  
  RESULTS
  Seven hundreds and thirty-two patients with a prostate tumor clinical stage of III or IV and 879 with a tumor clinical stage of I or II were diagnosed. The disease-specific survival rates at 1, 3 and 5 years were 94.6%, 81.3% and 72.6%, respectively. Five-year disease-specific survival rates were 99.2% for patients with low clinical stage PCa who underwent radical prostatectomy, 76.5% for those who underwent transurethral resection of the prostate plus hormone therapy, 38% for those who received hormone therapy plus radiation therapy and 29% for those that received hormone therapy alone.
  
  
  CONCLUSIONS
  In keeping with a lack of prostate-specific antigen (PSA)-based screening, Chinese men present later in life and course of their disease, with over 27% men dying of PCa at five years. Debulking of tumors by surgery and radiation therapy for high grade tumor may provide some survival benefit in the senior men but further study is required to validate these findings. It is important of the annual use of PSA test for men over 50 years old to detect the PCa in the early stage in this nation.
authors.affiliation: Department of Urology, Affiliated First Hospital of Suchow University, Suzhou Municipal Hospital, Suzhou, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Shao
authors.forename: Jun
authors.initials: J
authors.lastname: Ouyang
authors.forename: Youzhang
authors.initials: Y
authors.lastname: Fan
authors.forename: Jianjun
authors.initials: J
authors.lastname: Xie
authors.forename: Jundong
authors.initials: J
authors.lastname: Zhou
authors.forename: Jingchang
authors.initials: J
authors.lastname: Wu
authors.forename: A
authors.initials: A
authors.lastname: Karim Kader
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Xu
authors.forename: Guihua
authors.initials: G
authors.lastname: Liu
authors.forename: Yuxi
authors.initials: Y
authors.lastname: Shan
authors.forename: Duangai
authors.initials: D
authors.lastname: Wen
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D002681:China; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment; D012424:Rural Population / Q000706:statistics & numerical data; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen